EQS-News: M1 Kliniken AG
/ Key word(s): Quarterly / Interim Statement
M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result.
Berlin, 31 May 2023 - M1 Kliniken AG (ISIN: DE000A0STSQ8) announces figures for the first quarter of 2023. Accordingly, the consolidated group revenue of the M1 Group increased by around 21% to EUR 76.8 million in the first quarter (previous year: EUR 63.5 million). Consolidated EBITDA of the M1 Group totalled EUR 5.3 million in Q1 2023 (previous year: EUR 4.2 million), an increase of around 26%. Group EBIT increased by 44% to EUR 4.0 million (previous year: EUR 2.8 million). The Group EBIT margin increased from 4.4% to 5.3%. Sales and EBIT in the Beauty segment increased disproportionately in the first quarter of 2023. Sales increased by 51.7% from EUR 13.8 million to EUR 20.9 million. EBIT improved from EUR 1.7 million to EUR 3.6 million. The EBIT margin increased from 12.3% to 17.3%. The Beauty segment in the home market of Germany achieved sales of EUR 18.1 million and EBIT of EUR 4.1 million (Q1-2022: EUR 2.1 million). The EBIT margin in Germany thus amounted to 22.6%. The international beauty markets posted sales of EUR 2.8 million and EBIT of EUR -0.5 million (Q1 2022: EUR -0.4 million). With the opening of the 55th medical centre in Sofia/Bulgaria in May 2023, the Eastern European strategy was successfully continued. As a result, the M1 Group is now represented in nine countries. "Our expansion activities are fully on track and we expect to be able to open five more new locations in the current financial year. The focus is on the international national markets. The importance of foreign locations will increase considerably in the future. To this end, the Group is investing in brand awareness and reach in the country markets served," says the CEO of M1 Kliniken AG, Attila Strauss. The company's Annual General Meeting scheduled for 19 July 2023 will again be held in person. About M1 Kliniken AG M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 50 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with its internationalisation and is currently represented in nine countries. With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
31.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | M1 Kliniken AG |
Grünauer Straße 5 | |
12557 Berlin | |
Germany | |
Phone: | +49 (0)30 347 47 44 14 |
Fax: | +49 (0)30 347 47 44 17 |
E-mail: | ir@m1-kliniken.de |
Internet: | https://www.m1-kliniken.de |
ISIN: | DE000A0STSQ8 |
WKN: | A0STSQ |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1646407 |
End of News | EQS News Service |
|
1646407 31.05.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.